NASDAQ:ASNS Arsanis Stock Forecast, Price & News Notice: This company has been marked as potentially delisted and may not be actively trading. Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Arsanis, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $3.11 0.00 (0.00 %) (As of 03/13/2019) Add Compare Share Today's Range$3.05Now: $3.11▼$3.7850-Day Range$3.11MA: $3.11▼$3.1152-Week Range$1.15Now: $3.11▼$28.69Volume607,244 shsAverage Volume62,844 shsMarket Capitalization$45.53 millionP/E RatioN/ADividend YieldN/ABeta1.8 ProfileEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media X4 Pharmaceuticals, Inc. operates as a biotechnology company, which engages in developing human antibodies for treating infectious diseases. The company focuses on restoring healthy immune system function by developing novel therapeutics for the treatment of rare diseases. Its products in pipeline include X4P-001, X4P-002, and X4P-003. The company was founded by Henri A. Termeer, Keith T. Flaherty, Renato T. Skerlj, Richard Peters and Paula Ragan and is headquartered in Cambridge, MA.Read More HeadlinesX4 Pharmaceuticals: An OverviewNovember 14, 2019 | seekingalpha.comImara Appoints Chief Financial & Chief Operating Officer - Business WireApril 11, 2019 | www.businesswire.comThe Daily Biotech Pulse: Arsanis Completes X4 Merger, EC Nod For Roche, Axovant OfferingMarch 14, 2019 | finance.yahoo.comX4 Pharmaceuticals Completes Merger with ArsanisMarch 13, 2019 | www.businesswire.comArsanis, Inc. (ASNS)January 26, 2019 | seekingalpha.comArsanis files $150M mixed shelfJanuary 26, 2019 | seekingalpha.comArsanis Inc.December 13, 2018 | www.barrons.comSee More Headlines Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ASNS Previous Symbol CUSIPN/A CIK1501697 Webwww.arsanis.com Phone(857) 529-8300EmployeesN/AYear FoundedN/ADebt Debt-to-Equity Ratio0.37 Current Ratio6.50 Quick Ratio5.08 Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$3.50 million Price / Sales13.01 Cash FlowN/A Price / Cash FlowN/A Book Value$4.29 per share Price / Book0.72Profitability EPS (Most Recent Fiscal Year)($16.23) Net Income$-33,870,000.00 Net MarginsN/A Return on Equity-126.85% Return on Assets-82.61% Miscellaneous Outstanding Shares14,640,000Market Cap$45.53 million Next Earnings DateN/A OptionableNot Optionable MarketRank™Overall MarketRank™1.07 out of 5 starsMedical Sector985th out of 1,972 stocksBiotechnology Industry30th out of 125 stocksAnalyst Opinion: 0.0Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 - 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Arsanis. Previous Next 2.2 Community Rank Outperform VotesArsanis has received 279 “outperform” votes. (Add your “outperform” vote.)Underperform VotesArsanis has received 361 “underperform” votes. (Add your “underperform” vote.)Community SentimentArsanis has received 56.41% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Arsanis and other stocks. Vote “Outperform” if you believe ASNS will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ASNS will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldArsanis does not currently pay a dividend.Dividend GrowthArsanis does not have a long track record of dividend growth. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Arsanis insiders have not sold or bought any company stock.Percentage Held by Insiders50.90% of the stock of Arsanis is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions77.39% of the stock of Arsanis is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Arsanis is -0.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Arsanis is -0.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioArsanis has a P/B Ratio of 0.72. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Receive ASNS News and Ratings via Email Sign-up to receive the latest news and ratings for ASNS and its competitors with MarketBeat's FREE daily newsletter. Arsanis (NASDAQ:ASNS) Frequently Asked Questions What stocks does MarketBeat like better than Arsanis? Wall Street analysts have given Arsanis a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Arsanis wasn't one of them. MarketBeat thinks these five stocks may be even better buys.View MarketBeat's top stock picks here. How were Arsanis' earnings last quarter? Arsanis, Inc. (NASDAQ:ASNS) announced its earnings results on Friday, November, 9th. The company reported ($0.76) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.74) by $0.02. View Arsanis' earnings history. Who are Arsanis' key executives? Arsanis' management team includes the following people: Paula S. Ragan, President, Chief Executive Officer & DirectorAdam S. Mostafa, Chief Financial Officer & TreasurerCeleste DiJohnson, Vice President-Clinical OperationsMary DiBiase, Vice President-Technical Operations & QualityTarek Ebrahim, Vice President-Medical Affairs & Rare Disease Who are some of Arsanis' key competitors? Some companies that are related to Arsanis include Annovis Bio (ANVS), Ampliphi Biosciences (APHB), Redx Pharma Plc (REDX.L) (REDX), Oncolytics Biotech (ONC), 4D pharma (DDDD), Faron Pharmaceuticals Oy (FARN.L) (FARN), Vincerx Pharma (VINC), Mereo BioPharma Group plc (MPH.L) (MPH), Evaxion Biotech A/S (EVAX), Longeveron (LGVN), Verseon (VSN), ImmunoPrecise Antibodies Ltd. (IPA.V) (IPA), Helix BioPharma (HBP), Verona Pharma plc (VRP.L) (VRP) and Circassia Group (CIR). View all of ASNS's competitors. What other stocks do shareholders of Arsanis own? Based on aggregate information from My MarketBeat watchlists, some companies that other Arsanis investors own include Catalyst Pharmaceuticals (CPRX), NxStage Medical (NXTM), Selecta Biosciences (SELB), CDTi Advanced Materials (CDTI), Curis (CRIS), bluebird bio (BLUE), 1877 (JUNO), Nektar Therapeutics (NKTR), Protalix BioTherapeutics (PLX) and Tocagen (TOCA). When did Arsanis IPO? (ASNS) raised $50 million in an initial public offering on Thursday, November 16th 2017. The company issued 3,100,000 shares at a price of $15.00-$17.00 per share. Citigroup, Cowen and Piper Jaffray served as the underwriters for the IPO. What is Arsanis' stock symbol? Arsanis trades on the NASDAQ under the ticker symbol "ASNS." What is Arsanis' stock price today? One share of ASNS stock can currently be purchased for approximately $3.11. How much money does Arsanis make? Arsanis has a market capitalization of $45.53 million and generates $3.50 million in revenue each year. The company earns $-33,870,000.00 in net income (profit) each year or ($16.23) on an earnings per share basis. What is Arsanis' official website? The official website for Arsanis is www.arsanis.com. Where are Arsanis' headquarters? Arsanis is headquartered at 890 WINTER STREET SUITE 230, WALTHAM MA, 02451. How can I contact Arsanis? Arsanis' mailing address is 890 WINTER STREET SUITE 230, WALTHAM MA, 02451. The company can be reached via phone at (857) 529-8300 or via email at [email protected] This page was last updated on 3/5/2021 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here
